Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review.
Ontology highlight
ABSTRACT: Despite significant efforts, the rate of new HIV infections worldwide remains unacceptably high, highlighting the need for new HIV prevention strategies. HIV pre-exposure prophylaxis (PrEP) is a new approach that involves the ongoing use of antiretroviral medications by HIV-negative individuals to reduce the risk of HIV infection. The use of daily tenofovir/emtricitabine as oral PrEP was found to be effective in multiple placebo-controlled clinical trials and approved by the United States Food and Drug Administration. In addition, the Centers for Disease Control and Prevention in the United States and the World Health Organization have both released guidelines recommending the offer of oral PrEP to high-risk populations. The scale-up of PrEP is underway, but several implementation question
SUBMITTER: Wilton J
PROVIDER: S-EPMC4422285 | biostudies-literature | 2015
REPOSITORIES: biostudies-literature
ACCESS DATA